Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House ephedra hearings

This article was originally published in The Tan Sheet

Executive Summary

Energy & Commerce Committee ephedra investigation builds steam, with plans to hold two days of hearings in late July. Sports league heads, ephedra manufacturers, FDA reps likely will be called to testify. Committee chair Billy Tauzin (D-La.) and others send July 1 follow-up letter requesting FDA provide records on foreign ephedra investigations, AEs received since Sept. 30, 2001 close date of RAND report. Letter also requests records relating to FDA communications on the Boozer-Daly study often cited by ephedra proponents, and records relating to Hicksville, NY-based Phoenix Labs, which manufactured Xenadrine RFA-1 for Cytodyne. Investigation was launched in February with letters to McClellan, Cytodyne (1"The Tan Sheet" March 3, 2003, p. 9). Hearings for related inquiry into supplements marketed to children unlikely until after August recess...

You may also be interested in...

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts